View source for Dual GIP and GLP-1 receptor agonist

{{Short description|Dual GIP and GLP-1 receptor agonists, tirzepatide, Mounjaro, Zepbound, retatrutide, multi-receptor incretin therapy, weight loss, diabetes, and W8MD medical weight loss care}}
{{DISPLAYTITLE:Dual GIP and GLP-1 Receptor Agonist}}
__NOTOC__

{{Infobox drug class
| class = Dual GIP and GLP-1 receptor agonist
| image = [[File:Before-and-after-weight-loss.jpeg|250px]]
| caption = Dual GIP and GLP-1 receptor agonists act on two incretin pathways involved in insulin secretion, glucagon regulation, appetite, satiety, and body weight.
| type = Incretin-based therapy
| mechanisms = [[GIP receptor]] activation and [[GLP-1 receptor]] activation
| fda_approved_example = [[Tirzepatide]]
| brand_examples = [[Mounjaro]], [[Zepbound]]
| investigational_examples = [[Retatrutide]], VK2735
| related_classes = [[GLP-1 receptor agonist]], [[GIP receptor agonist]], [[Glucagon receptor agonist]], [[Anti-obesity medication]], [[Diabetes medication]]
| related = [[Tirzepatide weight loss]], [[Zepbound for weight loss]], [[Mounjaro for weight loss]], [[Tirzepatide and appetite]], [[GLP-1 weight loss injections]]
}}

<div style="max-width:1120px; margin:0 auto; font-size:1.05em; line-height:1.65;">

<div style="background:linear-gradient(135deg,#f5f9ff,#eef7f0); border:1px solid #c9ddf2; border-radius:16px; padding:28px; margin:20px 0; box-shadow:0 3px 10px rgba(0,0,0,0.08);">

[[File:Weight-loss-150.png|right|170px|link=GLP-1 weight loss injections|alt=W8MD dual GIP and GLP-1 receptor agonist medical weight loss care]]

<h1 style="margin-top:0; color:#1f4e79;">Dual GIP and GLP-1 Receptor Agonist</h1>

<p style="font-size:1.18em;">A '''dual GIP and GLP-1 receptor agonist''' is an [[incretin]]-based medication that activates both the [[glucose-dependent insulinotropic polypeptide receptor]] and the [[glucagon-like peptide-1 receptor]]. These two pathways help regulate [[insulin]] secretion, [[glucagon]], [[blood sugar]], [[appetite]], [[satiety]], [[gastric emptying]], [[food noise]], and [[body weight]].</p>

<p>The only FDA-approved medication in this class is '''[[tirzepatide]]''', marketed as '''[[Mounjaro]]''' for [[type 2 diabetes]] and '''[[Zepbound]]''' for [[chronic weight management]] and, in selected adults with obesity, moderate-to-severe [[obstructive sleep apnea]].<ref name="MounjaroLabel">{{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf|title=Mounjaro prescribing information|publisher=U.S. Food and Drug Administration|date=2026|accessdate=2026-07-13}}</ref><ref name="ZepboundLabel">{{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf|title=Zepbound prescribing information|publisher=U.S. Food and Drug Administration|date=2026|accessdate=2026-07-13}}</ref></p>

<p>At '''[[W8MD Weight Loss, Sleep and MedSpa]]''', experienced weight loss doctors can help patients compare dual GIP/GLP-1 therapy such as Zepbound, diabetes-focused Mounjaro education, semaglutide-based GLP-1 options, Wegovy, Wegovy pill, Wegovy HD, and emerging obesity medications to determine the safest and most effective patient-specific option.</p>

<div style="display:flex; flex-wrap:wrap; gap:14px; margin:22px 0;">

<div style="flex:1; min-width:220px; background:#ffffff; border:1px solid #b8d7f0; border-radius:12px; padding:16px; text-align:center;">
<div style="font-size:1.8em; font-weight:bold; color:#0b5cad;">Dual incretin</div>
<div>Targets both GIP and GLP-1 receptors.</div>
</div>

<div style="flex:1; min-width:220px; background:#ffffff; border:1px solid #b8d7f0; border-radius:12px; padding:16px; text-align:center;">
<div style="font-size:1.8em; font-weight:bold; color:#0b5cad;">Tirzepatide</div>
<div>Only FDA-approved dual GIP/GLP-1 agonist.</div>
</div>

<div style="flex:1; min-width:220px; background:#ffffff; border:1px solid #b8d7f0; border-radius:12px; padding:16px; text-align:center;">
<div style="font-size:1.8em; font-weight:bold; color:#0b5cad;">Retatrutide</div>
<div>Investigational triple GIP/GLP-1/glucagon receptor agonist.</div>
</div>

<div style="flex:1; min-width:220px; background:#ffffff; border:1px solid #b8d7f0; border-radius:12px; padding:16px; text-align:center;">
<div style="font-size:1.8em; font-weight:bold; color:#0b5cad;">W8MD guidance</div>
<div>Medication matching, prior authorization, affordability, nutrition, and maintenance.</div>
</div>

</div>

<div style="background:#fff8df; border:2px solid #f2c94c; border-radius:12px; padding:16px; margin:20px 0;">
'''W8MD patient benefit:''' W8MD can help determine whether [[Zepbound]], [[Mounjaro for weight loss]] education, tirzepatide-based options, [[Wegovy]], [[Wegovy pill]], [[Wegovy HD]], semaglutide-based options, or another medical weight-loss strategy is best for a patient’s diabetes status, appetite pattern, sleep apnea risk, cardiovascular risk, side-effect history, medication preference, insurance coverage, and budget.
</div>

<div style="background:#eef7f0; border:1px solid #b8dfc1; border-radius:12px; padding:16px; margin:20px 0;">
'''Affordable access at W8MD:''' W8MD offers tirzepatide-based options starting as low as '''$45.00 per week and up''' with insurance for qualifying visits, or '''$69.99 per week and up''' for self-pay patients when medically appropriate and available. W8MD also offers semaglutide-based options starting as low as '''$29.99 per week and up''' with insurance for qualifying visits, or '''$59.99 per week and up''' without insurance when medically appropriate and available. Pricing, medication access, pharmacy availability, insurance coverage, and eligibility vary by patient and location.
</div>

<div style="text-align:center; margin:24px 0;">
<span class="mw-ui-button mw-ui-progressive mw-ui-big">[https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-45198 Book Brooklyn Appointment]</span>
<span class="mw-ui-button mw-ui-progressive mw-ui-big">[https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-48161 Book Philadelphia Appointment]</span>
</div>

</div>

[[File:W8MD-Team.jpg|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] helps patients compare tirzepatide, semaglutide, Zepbound, Mounjaro, Wegovy, Wegovy HD, nutrition plans, sleep apnea care, insurance access, and long-term maintenance.]]
[[File:Woman-losing-weight.jpeg|thumb|right|350px|Dual GIP and GLP-1 therapy may improve appetite control, blood sugar, and weight loss, but best results require nutrition, activity, sleep, side-effect management, and medical follow-up.]]
[[File:Before-and-after-weight-loss.jpeg|thumb|right|350px|Before-and-after weight loss image. Individual results with tirzepatide or other incretin therapies vary and require medical supervision.]]
[[File:Body mass index chart.svg|thumb|right|300px|[[Body mass index]] is one tool used to determine eligibility for anti-obesity medications.]]
[[File:Obesity-waist circumference.svg|thumb|right|300px|[[Waist circumference]], [[central obesity]], and [[visceral fat]] are important markers of metabolic risk.]]
[[File:Sleep-150.png|thumb|right|220px|[[Sleep apnea]] can worsen hunger, fatigue, insulin resistance, cardiovascular risk, and weight regain. W8MD can arrange convenient [[home sleep study]] testing when appropriate.]]

==Overview==

A '''dual GIP and GLP-1 receptor agonist''' is a medication designed to activate two incretin hormone receptors:

* '''[[GIP receptor]]''' - the receptor for glucose-dependent insulinotropic polypeptide
* '''[[GLP-1 receptor]]''' - the receptor for glucagon-like peptide-1

These receptors are involved in meal-related insulin secretion, glucagon regulation, appetite control, satiety, gastric emptying, and body-weight regulation.

The best-known and currently FDA-approved example is '''[[tirzepatide]]'''. Tirzepatide is marketed as:

* '''[[Mounjaro]]''' - for [[type 2 diabetes]]
* '''[[Zepbound]]''' - for [[chronic weight management]] and selected adults with obesity and moderate-to-severe [[obstructive sleep apnea]]

==Quick facts==

<div style="background:#f8fbff; border:1px solid #d6e6f5; border-radius:14px; padding:22px; margin:22px 0;">

<h2 style="margin-top:0; color:#1f4e79;">Key points about dual GIP and GLP-1 receptor agonists</h2>

<div style="display:flex; flex-wrap:wrap; gap:14px; margin:16px 0;">

<div style="flex:1; min-width:230px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Insulin secretion'''<br />
The GIP component helps maximize the body’s meal-related insulin response, while incretin pathways help regulate glucagon.
</div>

<div style="flex:1; min-width:230px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Appetite suppression'''<br />
The GLP-1 component signals fullness to appetite centers and slows gastric emptying, helping reduce cravings and portions.
</div>

<div style="flex:1; min-width:230px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Weight and A1c reduction'''<br />
Clinical trials of tirzepatide show strong reductions in body weight and A1c compared with placebo and several active comparators.
</div>

<div style="flex:1; min-width:230px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Not one-size-fits-all'''<br />
Medication choice depends on diabetes, obesity, sleep apnea, side effects, insurance, cost, availability, and patient preference.
</div>

</div>

</div>

==How GIP and GLP-1 work together==

Dual GIP and GLP-1 receptor agonists combine two incretin pathways.

{| class="wikitable" style="width:100%;"
! Pathway
! Full name
! Main physiologic role
! Medication relevance
|-
| '''GIP'''
| [[Glucose-dependent insulinotropic polypeptide]]
| Enhances glucose-dependent insulin secretion after meals and may influence adipose tissue, appetite, and energy balance
| In tirzepatide, GIP receptor activation works with GLP-1 receptor activation to improve glycemic control and body-weight reduction
|-
| '''GLP-1'''
| [[Glucagon-like peptide-1]]
| Increases glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, increases satiety, and reduces appetite
| GLP-1 receptor activation is central to appetite suppression, reduced calorie intake, and many gastrointestinal side effects
|}

Mounjaro and Zepbound prescribing information describe tirzepatide as a GIP receptor and GLP-1 receptor agonist.<ref name="MounjaroLabel" /><ref name="ZepboundLabel" />

==Insulin secretion and glucagon regulation==

After meals, incretin hormones help the body respond to rising glucose. Dual GIP and GLP-1 receptor activation may improve glucose regulation by:

{{div col|colwidth=20em}}
* Increasing glucose-dependent insulin secretion
* Improving post-meal insulin response
* Reducing inappropriate glucagon secretion
* Improving glycemic control
* Reducing A1c in patients with type 2 diabetes
* Supporting weight loss, which may improve insulin resistance
{{div col end}}

The GIP component helps improve the body’s ability to release insulin after meals, while GLP-1 receptor activation also supports insulin secretion and glucagon regulation in a glucose-dependent way.

==Appetite suppression and food noise==

The GLP-1 component is strongly linked with appetite suppression. GLP-1 receptor activation can signal fullness to the brain and slow stomach emptying, which may reduce hunger, cravings, food noise, and portion size.

Patients may notice:

{{div col|colwidth=18em}}
* Less hunger between meals
* Feeling full sooner
* Less urge to snack
* Less evening eating
* Fewer cravings
* Reduced food noise
* Smaller portions
* Better control around trigger foods
{{div col end}}

See also [[Tirzepatide and appetite]] and [[Semaglutide and appetite]].

==Why dual GIP and GLP-1 therapy may produce strong weight loss==

Tirzepatide’s dual mechanism may contribute to strong weight-loss results through multiple pathways:

{{div col|colwidth=20em}}
* Reduced appetite
* Reduced calorie intake
* Improved satiety
* Delayed gastric emptying
* Improved insulin secretion
* Reduced glucagon
* Improved insulin sensitivity
* Effects on energy balance
* Reduction in fat mass
* Better control of food noise and cravings
{{div col end}}

In SURMOUNT-1, adults with obesity or overweight without diabetes had mean body-weight reductions of 15.0%, 19.5%, and 20.9% with tirzepatide 5 mg, 10 mg, and 15 mg, respectively, compared with 3.1% with placebo.<ref name="SURMOUNT1">{{cite journal|last1=Jastreboff|first1=A. M.|title=Tirzepatide Once Weekly for the Treatment of Obesity|journal=New England Journal of Medicine|year=2022|volume=387|issue=3|pages=205-216|doi=10.1056/NEJMoa2206038|pmid=35658024}}</ref>

==Weight and A1c reduction==

Dual GIP and GLP-1 therapy is clinically important because it addresses both weight and glycemic control.

{| class="wikitable" style="width:100%;"
! Outcome
! Why it matters
! Tirzepatide relevance
|-
| '''A1c reduction'''
| Lower A1c reduces hyperglycemia burden in type 2 diabetes
| Mounjaro is FDA-approved to improve glycemic control in type 2 diabetes
|-
| '''Weight loss'''
| Weight reduction can improve insulin resistance, blood pressure, sleep apnea, fatty liver risk, and mobility
| Zepbound is FDA-approved for chronic weight management in selected adults
|-
| '''Appetite control'''
| Appetite and cravings are major barriers to long-term weight loss
| Tirzepatide can reduce calorie intake and appetite in many patients
|-
| '''Maintenance'''
| Obesity is chronic and relapsing
| Continued therapy may be needed for many patients to maintain results
|}

In SURPASS-2, tirzepatide produced greater reductions in glycated hemoglobin and body weight than semaglutide 1 mg in patients with type 2 diabetes.<ref name="SURPASS2">{{cite journal|last1=Frías|first1=J. P.|title=Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes|journal=New England Journal of Medicine|year=2021|volume=385|issue=6|pages=503-515|doi=10.1056/NEJMoa2107519|pmid=34170647}}</ref>

==Currently FDA-approved medication in this class==

As of the latest reviewed FDA labeling, the only FDA-approved medication in the dual GIP and GLP-1 receptor agonist class is '''tirzepatide'''.

{| class="wikitable" style="width:100%;"
! Generic name
! Brand name
! FDA-approved use
! Route
! W8MD patient education point
|-
| '''[[Tirzepatide]]'''
| '''[[Mounjaro]]'''
| [[Type 2 diabetes]]
| Once-weekly subcutaneous injection
| Diabetes brand; may also cause weight loss, but Zepbound is the weight-management brand
|-
| '''[[Tirzepatide]]'''
| '''[[Zepbound]]'''
| [[Chronic weight management]] in selected adults; moderate-to-severe [[obstructive sleep apnea]] in adults with obesity
| Once-weekly subcutaneous injection
| Weight-management and sleep-apnea brand; often the preferred tirzepatide brand when obesity treatment is the primary indication
|}

==Tirzepatide==

'''Tirzepatide''' is a synthetic peptide that activates the GIP and GLP-1 receptors. It is given as a once-weekly injection.

Important features include:

{{div col|colwidth=20em}}
* Dual GIP and GLP-1 receptor activation
* Once-weekly dosing
* Strong A1c reduction in type 2 diabetes
* Substantial weight loss in obesity trials
* Appetite and calorie-intake reduction
* Gradual dose escalation
* Common gastrointestinal side effects
* Long-term maintenance considerations
{{div col end}}

==Mounjaro==

'''Mounjaro''' is the tirzepatide brand used for [[type 2 diabetes]]. It is used with diet and exercise to improve blood sugar control.

Patients often ask about Mounjaro for weight loss because weight reduction is commonly seen in diabetes trials. However, for chronic weight management, the tirzepatide brand is [[Zepbound]].

Mounjaro may be considered when the primary medical indication is type 2 diabetes and the clinician determines that tirzepatide is appropriate based on A1c, weight, comorbidities, contraindications, insurance coverage, and patient preference.

==Zepbound==

'''Zepbound''' is the tirzepatide brand used for chronic weight management. The FDA approved Zepbound in November 2023 for adults with obesity or overweight with at least one weight-related condition, used in addition to a reduced-calorie diet and increased physical activity.<ref name="FDAZepboundWeight">{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management|title=FDA Approves New Medication for Chronic Weight Management|publisher=U.S. Food and Drug Administration|date=2023-11-08|accessdate=2026-07-13}}</ref>

Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.<ref name="FDAZepboundOSA">{{cite web|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea|title=FDA Approves First Medication for Obstructive Sleep Apnea|publisher=U.S. Food and Drug Administration|date=2024-12-20|accessdate=2026-07-13}}</ref>

==Investigational and emerging multi-receptor medications==

Several medications are being studied that act on GIP, GLP-1, glucagon, or related incretin pathways. These are not all in the same class, and not all are dual GIP/GLP-1 receptor agonists.

{| class="wikitable" style="width:100%;"
! Medication
! Mechanism
! Status
! Why it matters
|-
| '''[[Retatrutide]]'''
| Triple agonist: GIP receptor, GLP-1 receptor, and glucagon receptor activation
| Investigational, not FDA-approved
| Adds glucagon receptor activation as a third mechanism; studied for obesity, type 2 diabetes, and related complications
|-
| '''VK2735'''
| Dual GLP-1/GIP receptor agonist
| Investigational, not FDA-approved
| Phase 2 obesity data reported meaningful short-term weight loss; phase 3 program has been described
|-
| '''Maridebart cafraglutide / MariTide'''
| GLP-1 receptor agonist plus GIP receptor antagonist activity
| Investigational, not FDA-approved
| Related multi-pathway incretin strategy, but not a dual GIP/GLP-1 agonist
|-
| '''CagriSema'''
| Amylin analog plus semaglutide GLP-1 receptor agonist
| Investigational or jurisdiction-dependent depending on timing and location
| Combination metabolic therapy, but not a GIP/GLP-1 dual agonist
|-
| '''Survodutide'''
| GLP-1 receptor and glucagon receptor dual agonist
| Investigational, not FDA-approved for obesity in the United States
| Related multi-receptor obesity approach, but does not activate GIP
|}

==Retatrutide: triple GIP, GLP-1, and glucagon receptor agonist==

'''Retatrutide''' is an investigational triple hormone receptor agonist that activates:

* [[GIP receptor]]
* [[GLP-1 receptor]]
* [[Glucagon receptor]]

The third mechanism, glucagon receptor activation, may increase energy expenditure and influence liver metabolism, while GIP and GLP-1 pathways support appetite, insulin, glucagon, and weight regulation.

In a phase 2 obesity trial, once-weekly retatrutide produced substantial dose-dependent body-weight reductions at 24 and 48 weeks, and the authors concluded that the results supported further phase 3 investigation.<ref name="RetatrutideNEJM">{{cite journal|last1=Jastreboff|first1=A. M.|title=Triple-Hormone-Receptor Agonist Retatrutide for Obesity|journal=New England Journal of Medicine|year=2023|volume=389|issue=6|pages=514-526|doi=10.1056/NEJMoa2301972|pmid=37366315}}</ref>

Retatrutide remains investigational and is not FDA-approved. Patients should not purchase or use research peptides or unapproved retatrutide products outside legitimate clinical trials.

==Retatrutide phase 3 data==

Retatrutide has moved into phase 3 development. A 2026 Lancet abstract describes retatrutide as a GIP, GLP-1, and glucagon triple hormone receptor agonist under clinical development for type 2 diabetes, obesity, and related complications.<ref name="RetatrutideLancet">{{cite web|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00967-0/abstract|title=Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist in type 2 diabetes|publisher=The Lancet|date=2026|accessdate=2026-07-13}}</ref>

Lilly has also reported phase 3 obesity results for retatrutide in TRIUMPH-1, including up to 28.3% average weight loss at 80 weeks with the 12 mg dose in a company release. Because regulatory review and peer-reviewed publication status may change, patients should treat retatrutide as investigational unless and until it receives FDA approval.<ref name="LillyRetatrutideTRIUMPH">{{cite web|url=https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html|title=Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial|publisher=Eli Lilly and Company|date=2026-05-21|accessdate=2026-07-13}}</ref>

==VK2735==

'''VK2735''' is an investigational dual GLP-1/GIP receptor agonist being studied for weight management. A phase 2 VENTURE study reported meaningful weight reduction over 13 weeks, and the developer has described a phase 3 VANQUISH obesity program.<ref name="VK2735">{{cite web|url=https://ir.vikingtherapeutics.com/2026-01-12-Viking-Therapeutics-Announces-Publication-of-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-the-Journal-Obesity|title=Publication of Phase 2 VENTURE trial of dual GLP-1/GIP receptor agonist VK2735|publisher=Viking Therapeutics|date=2026-01-12|accessdate=2026-07-13}}</ref>

VK2735 is not FDA-approved. It should be considered investigational unless approved by regulators.

==MariTide and related incretin approaches==

'''MariTide''' or maridebart cafraglutide is an investigational long-acting therapy described as a GLP-1 receptor agonist and GIP receptor antagonist, not a dual GIP/GLP-1 receptor agonist. In phase 2 data, it has been studied for obesity and type 2 diabetes and has attracted interest because of possible less-frequent dosing.<ref name="MariTideNEJM">{{cite journal|title=Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity|journal=New England Journal of Medicine|year=2025|doi=10.1056/NEJMoa2504214}}</ref>

This illustrates how obesity pharmacotherapy is expanding beyond single GLP-1 receptor agonists into multi-pathway metabolic treatments.

==Comparison: GLP-1, dual GIP/GLP-1, and triple agonists==

{| class="wikitable" style="width:100%;"
! Category
! Receptors targeted
! Example
! Status
! Main clinical idea
|-
| '''Single GLP-1 receptor agonist'''
| GLP-1
| [[Semaglutide]], [[liraglutide]]
| Several FDA-approved products
| Appetite reduction, delayed gastric emptying, glucose-dependent insulin secretion
|-
| '''Dual GIP and GLP-1 receptor agonist'''
| GIP and GLP-1
| [[Tirzepatide]]
| FDA-approved as Mounjaro and Zepbound
| Strong glycemic control and weight loss through two incretin pathways
|-
| '''Triple GIP, GLP-1, and glucagon receptor agonist'''
| GIP, GLP-1, and glucagon
| [[Retatrutide]]
| Investigational
| Adds glucagon receptor activity that may influence energy expenditure and liver metabolism
|-
| '''GLP-1 plus GIP receptor antagonist'''
| GLP-1 agonism plus GIP receptor antagonism
| MariTide
| Investigational
| Alternative multi-pathway incretin strategy with possible less frequent dosing
|}

==Are dual GIP and GLP-1 receptor agonists superior to standard GLP-1 drugs?==

Clinical trials have shown that tirzepatide can produce greater weight loss and A1c reduction than some single-receptor GLP-1 receptor agonist comparators in studied populations.

Important evidence includes:

{{div col|colwidth=20em}}
* SURPASS-2: Tirzepatide reduced A1c and body weight more than semaglutide 1 mg in type 2 diabetes.<ref name="SURPASS2" />
* SURMOUNT-1: Tirzepatide produced up to 20.9% mean body-weight reduction in adults with obesity or overweight without diabetes.<ref name="SURMOUNT1" />
* SURMOUNT-5: Tirzepatide was superior to semaglutide injection for body-weight and waist-circumference reduction in adults with obesity or overweight without diabetes.<ref name="SURMOUNT5">{{cite journal|last1=Aronne|first1=L. J.|title=Tirzepatide as Compared with Semaglutide for the Treatment of Obesity|journal=New England Journal of Medicine|year=2025|doi=10.1056/NEJMoa2416394|pmid=40353578}}</ref>
{{div col end}}

However, “superior average result” does not mean “best for every patient.” Some patients do better with semaglutide, Wegovy, Ozempic, Wegovy pill, Wegovy HD, or non-GLP-1 treatments because of tolerability, cost, coverage, contraindications, medical history, or personal preference.

==Do dual GIP and GLP-1 agonists reduce side effects?==

<div style="background:#fff3cd; border:1px solid #ffe08a; border-radius:12px; padding:16px; margin:20px 0;">
'''Evidence-based caution:''' Dual GIP and GLP-1 receptor activation may improve weight-loss efficacy and glycemic outcomes, but it does not eliminate side effects. Nausea, diarrhea, vomiting, constipation, reflux, abdominal discomfort, fatigue, and injection-site reactions remain common with tirzepatide, especially during dose escalation. Some patients tolerate tirzepatide better than semaglutide; others tolerate semaglutide better. The best medication is patient-specific.
</div>

Side effects may be reduced in practice by:

{{div col|colwidth=20em}}
* Starting low
* Escalating slowly
* Holding dose longer if needed
* Avoiding large or greasy meals
* Treating constipation early
* Staying hydrated
* Prioritizing protein
* Avoiding excessive appetite suppression
* Adjusting medication when side effects occur
* Switching treatment when medically appropriate
{{div col end}}

==Common side effects==

Common side effects of tirzepatide and related incretin therapies are often gastrointestinal.

{{div col|colwidth=18em}}
* [[Nausea]]
* [[Diarrhea]]
* [[Vomiting]]
* [[Constipation]]
* Abdominal discomfort
* [[Gastroesophageal reflux disease]]
* Burping
* Bloating
* Reduced appetite
* Fatigue
* Injection-site reactions
* Hair loss related to rapid weight loss in some patients
{{div col end}}

Zepbound labeling lists common adverse reactions including nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease.<ref name="ZepboundLabel" />

==Safety considerations==

Dual GIP and GLP-1 receptor agonists are not appropriate for everyone.

Patients should discuss risks with a healthcare provider if they have:

{{div col|colwidth=20em}}
* Personal or family history of [[medullary thyroid carcinoma]]
* [[Multiple Endocrine Neoplasia syndrome type 2]]
* Prior serious allergic reaction to tirzepatide
* History of [[pancreatitis]]
* [[Gallbladder disease]]
* Severe gastrointestinal disease
* [[Kidney disease]]
* Diabetes medications that can cause hypoglycemia
* [[Diabetic retinopathy]]
* Pregnancy or plans for pregnancy
* Breastfeeding
* Eating disorder history
* Severe dehydration risk
{{div col end}}

==Who may benefit from tirzepatide or dual incretin therapy?==

A patient may be considered for tirzepatide-based therapy when medically appropriate if they have:

{{div col|colwidth=20em}}
* [[Type 2 diabetes]]
* [[Obesity]]
* [[Overweight]] with weight-related conditions
* [[Prediabetes]]
* [[Insulin resistance]]
* [[Hypertension]]
* [[Dyslipidemia]]
* [[Sleep apnea]]
* [[Metabolic syndrome]]
* Strong appetite or food noise
* Need for substantial weight reduction
* Prior inadequate response to lifestyle therapy alone
* Need for long-term maintenance support
{{div col end}}

Final eligibility depends on the exact indication, medication label, medical history, contraindications, insurance coverage, availability, and clinician judgment.

==How W8MD chooses the best medication for each patient==

<div style="background:#f8fbff; border:1px solid #d6e6f5; border-radius:14px; padding:22px; margin:22px 0;">

<h2 style="margin-top:0; color:#1f4e79;">W8MD patient-specific medication selection</h2>

<div style="display:flex; flex-wrap:wrap; gap:14px; margin:16px 0;">

<div style="flex:1; min-width:240px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Diabetes and A1c'''<br />
Patients with type 2 diabetes may need a diabetes-focused plan such as Mounjaro or Ozempic education, depending on coverage and medical history.
</div>

<div style="flex:1; min-width:240px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Weight-loss goal'''<br />
Patients needing substantial weight reduction may be candidates for Zepbound, Wegovy HD, Wegovy, or another medically appropriate option.
</div>

<div style="flex:1; min-width:240px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Tolerability'''<br />
W8MD reviews nausea, reflux, constipation, appetite suppression, dehydration risk, and prior GLP-1 side effects before choosing a plan.
</div>

<div style="flex:1; min-width:240px; background:#ffffff; border-left:5px solid #0b5cad; border-radius:10px; padding:16px;">
'''Coverage and cost'''<br />
W8MD can help with prior authorization when coverage is available and can discuss affordable semaglutide or tirzepatide-based options.
</div>

</div>

</div>

W8MD considers:

{{div col|colwidth=20em}}
* Current weight
* [[BMI]]
* Waist circumference
* A1c and diabetes status
* Blood pressure
* Cholesterol
* Sleep apnea symptoms
* Cardiovascular history
* Kidney function
* Liver and fatty liver risk
* Appetite and food noise
* Prior GLP-1 response
* Side-effect history
* Injection preference
* Pill preference
* Insurance coverage
* Pharmacy availability
* Cost and affordability
* Long-term maintenance goals
{{div col end}}

==How W8MD can help==

W8MD helps eligible patients with:

{{div col|colwidth=20em}}
* [[Dual GIP and GLP-1 receptor agonist]] education
* [[Tirzepatide weight loss]]
* [[Tirzepatide injection]]
* [[Tirzepatide dose escalation]]
* [[Tirzepatide side effects]]
* [[Tirzepatide maintenance therapy]]
* [[Tirzepatide and appetite]]
* [[Zepbound for weight loss]]
* [[Zepbound for sleep apnea]]
* [[Mounjaro for weight loss]] education
* Tirzepatide-based options
* [[Semaglutide weight loss]]
* [[Wegovy for weight loss]]
* [[Wegovy pill]]
* [[Wegovy HD]]
* [[Ozempic for weight loss]] education
* Prior authorization support when coverage is available
* Affordable medication options when medically appropriate
* Nutrition and protein planning
* [[Meal replacements]]
* [[Low-carbohydrate diet]] counseling
* [[Exercise counseling]]
* [[Resistance training]]
* [[Sleep apnea screening]]
* [[Home sleep study]]
* Long-term [[weight maintenance]]
{{div col end}}

==W8MD success story themes==

<div style="background:#eef7f0; border:1px solid #b8dfc1; border-radius:14px; padding:22px; margin:22px 0;">

<h2 style="margin-top:0; color:#1f4e79;">What successful W8MD patients often notice</h2>

<p>Since 2011, W8MD has helped thousands of patients work toward healthier weight, improved metabolism, better sleep, and long-term maintenance. Individual results vary, but successful patients often describe several common themes:</p>

<div style="display:flex; flex-wrap:wrap; gap:14px;">

<div style="flex:1; min-width:230px; background:#ffffff; border-radius:10px; padding:16px; text-align:center;">
<div style="font-size:1.7em; font-weight:bold; color:#237a3b;">Better matching</div>
<div>Patients do better when the medication matches their diabetes status, appetite pattern, coverage, and side-effect history.</div>
</div>

<div style="flex:1; min-width:230px; background:#ffffff; border-radius:10px; padding:16px; text-align:center;">
<div style="font-size:1.7em; font-weight:bold; color:#237a3b;">Less food noise</div>
<div>Many patients report fewer constant food thoughts, reduced cravings, and smaller portions.</div>
</div>

<div style="flex:1; min-width:230px; background:#ffffff; border-radius:10px; padding:16px; text-align:center;">
<div style="font-size:1.7em; font-weight:bold; color:#237a3b;">Improved confidence</div>
<div>Education on dose escalation, injection technique, and side effects can make treatment less intimidating.</div>
</div>

<div style="flex:1; min-width:230px; background:#ffffff; border-radius:10px; padding:16px; text-align:center;">
<div style="font-size:1.7em; font-weight:bold; color:#237a3b;">Maintenance focus</div>
<div>W8MD emphasizes long-term maintenance rather than short-term medication starts.</div>
</div>

</div>

<p style="margin-top:18px;">These are general success themes and not a guarantee of results. Outcomes depend on medical history, dose, adherence, nutrition, activity, sleep, side effects, medication access, and follow-up.</p>

</div>

==Insurance prior authorization and affordability==

Insurance coverage varies widely by medication, diagnosis, plan, and pharmacy benefit rules. Some plans cover Zepbound for weight management; some cover Mounjaro for type 2 diabetes; some exclude anti-obesity medications; and some require step therapy or prior authorization.

W8MD can help when coverage is available by documenting:

{{div col|colwidth=20em}}
* Current [[BMI]]
* Starting weight and current weight
* Weight-related medical conditions
* Type 2 diabetes status
* A1c and metabolic history
* Sleep apnea diagnosis when relevant
* Prior weight-loss attempts
* Prior medication history
* Side-effect history
* Dose history and response
* Medical necessity
* Follow-up visit documentation
{{div col end}}

Approval is not guaranteed. Insurance decisions depend on plan rules, exclusions, diagnosis, medication criteria, pharmacy benefit policies, and medication availability.

==Affordable tirzepatide and semaglutide options at W8MD==

<div style="border:2px solid #f2c94c; background:#fff8df; padding:18px; margin:18px 0; border-radius:12px; box-shadow:0 2px 8px rgba(0,0,0,0.06);">

<h3 style="margin-top:0; color:#8a5a00;">Affordable incretin-based weight-loss care</h3>

W8MD helps eligible patients access physician-supervised GLP-1 and GIP/GLP-1 treatment when medically appropriate.

* '''Tirzepatide-based options starting as low as $45.00 per week and up''' with insurance for qualifying visits.
* '''Self-pay tirzepatide-based options starting from $69.99 per week and up''' when available and medically appropriate.
* '''Semaglutide-based options starting as low as $29.99 per week and up''' with insurance for qualifying visits.
* '''Self-pay semaglutide-based options starting from $59.99 per week and up''' when available and medically appropriate.
* '''Most insurances accepted for qualifying medical visits.'''
* W8MD can help with prior authorization for brand-name medications when coverage is available.
* Pricing, insurance coverage, medication access, pharmacy availability, state rules, and eligibility vary by patient, location, and medical evaluation.

<div style="text-align:center; margin-top:18px;">
<span class="mw-ui-button mw-ui-progressive mw-ui-big">[https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-45198 Book Brooklyn Appointment]</span>
<span class="mw-ui-button mw-ui-progressive mw-ui-big">[https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-48161 Book Philadelphia Appointment]</span>
</div>

</div>

==Avoid unsafe online products==

Patients should avoid unapproved online “research” peptides, counterfeit Mounjaro, counterfeit Zepbound, counterfeit tirzepatide, unapproved retatrutide, and products marketed without legitimate medical supervision. The FDA has warned about concerns with unapproved GLP-1 drugs used for weight loss, including compounded semaglutide and tirzepatide products with safety concerns.<ref name="FDAUnapprovedGLP1">{{cite web|url=https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss|title=FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss|publisher=U.S. Food and Drug Administration|date=2026-06-15|accessdate=2026-07-13}}</ref>

Safe treatment requires:

{{div col|colwidth=18em}}
* A qualified prescriber
* Correct diagnosis
* Correct product and dose
* Clear pharmacy source
* Proper injection instructions
* Side-effect monitoring
* Nutrition support
* Follow-up care
{{div col end}}

==Dual GIP and GLP-1 receptor agonist near me==

Patients searching for '''dual GIP and GLP-1 receptor agonist near me''', '''tirzepatide doctor NYC''', '''Zepbound doctor Brooklyn''', '''Mounjaro weight loss New Jersey''', '''GIP GLP-1 weight loss Philadelphia''', '''tirzepatide injections Pennsylvania''', '''Zepbound sleep apnea prior authorization''', '''affordable tirzepatide NYC''', or '''GLP-1 weight loss doctor Delaware''' often want a medical practice that can compare medications, explain mechanisms, manage side effects, and help with insurance access.

W8MD serves patients in and around:

{{div col|colwidth=18em}}
* [[Brooklyn]]
* [[New York City]]
* [[Manhattan]]
* [[Queens]]
* [[Staten Island]]
* [[Long Island]]
* [[New Jersey]]
* [[Connecticut]]
* [[Philadelphia]]
* [[Pennsylvania]]
* [[Delaware]]
* [[Greater Philadelphia]]
{{div col end}}

Services and medication options may vary by location, state rules, insurance plan, pharmacy availability, and clinical evaluation.

==Frequently asked questions==

===What is a dual GIP and GLP-1 receptor agonist?===

A dual GIP and GLP-1 receptor agonist is a medication that activates both the GIP receptor and GLP-1 receptor. These pathways help regulate insulin, glucagon, appetite, satiety, blood sugar, and body weight.

===What is the only FDA-approved dual GIP and GLP-1 receptor agonist?===

The only FDA-approved medication in this class is tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and selected obstructive sleep apnea use in adults with obesity.<ref name="MounjaroLabel" /><ref name="ZepboundLabel" />

===How does the GIP component work?===

The GIP component helps improve glucose-dependent insulin secretion after meals and may contribute to energy balance and metabolic effects.

===How does the GLP-1 component work?===

The GLP-1 component increases glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, signals fullness, reduces appetite, and helps reduce calorie intake.

===Do dual GIP and GLP-1 receptor agonists reduce appetite?===

Yes, tirzepatide can reduce appetite and calorie intake in many patients. Appetite effects vary by patient, dose, sleep, side effects, and adherence.

===Are dual GIP and GLP-1 agonists better than GLP-1-only medications?===

Tirzepatide has shown superior weight-loss and A1c results compared with some GLP-1-only comparators in clinical trials, but the best medication depends on the individual patient.

===Does tirzepatide have fewer side effects than semaglutide?===

Not always. Some patients tolerate tirzepatide better, while others tolerate semaglutide better. Both can cause gastrointestinal side effects. W8MD can help choose and adjust therapy based on tolerability.

===What is retatrutide?===

Retatrutide is an investigational triple receptor agonist that activates GIP, GLP-1, and glucagon receptors. It is not FDA-approved as of this writing.

===Why does glucagon receptor activation matter in retatrutide?===

Glucagon receptor activation may increase energy expenditure and affect liver metabolism, potentially adding another mechanism for weight loss. Because retatrutide is investigational, its long-term safety and final approved use remain under study.

===Can W8MD help me choose between Zepbound, Mounjaro, Wegovy, and Wegovy HD?===

Yes. W8MD can compare medications based on diabetes status, weight-loss goal, appetite, sleep apnea, side effects, contraindications, insurance coverage, cost, and patient preference.

===Can W8MD help with insurance prior authorization?===

Yes. When coverage is available and criteria are met, W8MD can help document BMI, weight-related conditions, type 2 diabetes, sleep apnea, prior treatments, medication response, and medical necessity. Approval depends on the insurance plan.

==Book a dual GIP and GLP-1 receptor agonist consultation==

<div style="background:linear-gradient(135deg,#f5f9ff,#eef7f0); border:1px solid #c9ddf2; border-radius:16px; padding:24px; margin:28px 0; box-shadow:0 3px 10px rgba(0,0,0,0.08);">

[[File:W8MD-Team.jpg|right|220px|link=W8MD Weight Loss, Sleep and MedSpa|alt=W8MD Weight Loss Sleep and MedSpa team]]

<h2 style="margin-top:0; color:#1f4e79;">Request an appointment with W8MD</h2>

<p>W8MD offers physician-supervised [[medical weight loss]], [[dual GIP and GLP-1 receptor agonist]] education, [[tirzepatide weight loss]], [[Zepbound for weight loss]], [[Zepbound for sleep apnea]], [[Mounjaro for weight loss]] education, [[Wegovy for weight loss]], [[Wegovy HD]], [[GLP-1 weight loss injections]], insurance prior authorization support when coverage is available, affordable semaglutide and tirzepatide-based options, nutrition support, sleep medicine, and long-term maintenance care in Brooklyn, NY and Philadelphia, PA.</p>

<div style="display:flex; flex-wrap:wrap; gap:16px; margin:20px 0;">

<div style="flex:1; min-width:280px; background:#ffffff; border:1px solid #b8d7f0; border-radius:12px; padding:20px;">
<h3 style="margin-top:0; color:#1f4e79;">Brooklyn, NY Office</h3>
<p><strong>Phone:</strong> <span style="font-size:1.25em; color:#0b5cad; font-weight:bold;">718-946-5500</span></p>
<p>For patients searching for [[tirzepatide doctor Brooklyn]], [[Zepbound NYC]], [[Mounjaro weight loss New Jersey]], [[dual GIP GLP-1 doctor NYC]], or [[GLP-1 weight loss shots NYC]].</p>
<span class="mw-ui-button mw-ui-progressive mw-ui-big">[https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-45198 Book Brooklyn Appointment]</span>
</div>

<div style="flex:1; min-width:280px; background:#ffffff; border:1px solid #b8d7f0; border-radius:12px; padding:20px;">
<h3 style="margin-top:0; color:#1f4e79;">Philadelphia, PA Office</h3>
<p><strong>Phone:</strong> <span style="font-size:1.25em; color:#0b5cad; font-weight:bold;">215-676-2334</span></p>
<p>For patients searching for [[tirzepatide doctor Philadelphia]], [[Zepbound Pennsylvania]], [[Mounjaro weight loss Delaware]], [[dual GIP GLP-1 doctor Philadelphia]], or [[GLP-1 shots Philadelphia]].</p>
<span class="mw-ui-button mw-ui-progressive mw-ui-big">[https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-48161 Book Philadelphia Appointment]</span>
</div>

</div>

<div style="background:#fff3cd; border:1px solid #ffe08a; border-radius:10px; padding:14px; margin:18px 0;">
'''Important:''' Please do not submit sensitive medical information, Social Security numbers, insurance ID numbers, or urgent medical concerns through online appointment request forms. If this is a medical emergency, call '''911'''.
</div>

</div>

==Related W8MD and GLP-1 pages==

{{div col|colwidth=18em}}
* [[GLP-1 weight loss injections]]
* [[Dual GIP and GLP-1 receptor agonist]]
* [[Tirzepatide weight loss]]
* [[Tirzepatide injection]]
* [[Tirzepatide dose escalation]]
* [[Tirzepatide side effects]]
* [[Tirzepatide maintenance therapy]]
* [[Tirzepatide and appetite]]
* [[Tirzepatide and sleep apnea]]
* [[Zepbound for weight loss]]
* [[Zepbound for sleep apnea]]
* [[Mounjaro for weight loss]]
* [[Semaglutide weight loss]]
* [[Semaglutide and appetite]]
* [[Wegovy for weight loss]]
* [[Wegovy pill]]
* [[Wegovy HD]]
* [[Ozempic for weight loss]]
* [[Retatrutide]]
* [[Food noise]]
* [[Satiety]]
* [[Appetite regulation]]
* [[Gastric emptying]]
* [[Chronic weight management]]
* [[Sleep apnea screening]]
* [[Home sleep study]]
* [[Medical weight loss]]
* [[Obesity medicine]]
{{div col end}}

==Relevant WikiMD links==

* [https://wikimd.org/wiki/Tirzepatide Tirzepatide on WikiMD]
* [https://wikimd.org/wiki/Zepbound Zepbound on WikiMD]
* [https://wikimd.org/wiki/Mounjaro Mounjaro on WikiMD]
* [https://wikimd.org/wiki/Semaglutide Semaglutide on WikiMD]
* [https://wikimd.org/wiki/Wegovy Wegovy on WikiMD]
* [https://wikimd.org/wiki/GLP-1_receptor_agonist GLP-1 receptor agonist on WikiMD]
* [https://wikimd.org/wiki/Appetite Appetite on WikiMD]
* [https://wikimd.org/wiki/Satiety Satiety on WikiMD]
* [https://wikimd.org/wiki/Gastric_emptying Gastric emptying on WikiMD]
* [https://wikimd.org/wiki/Insulin Insulin on WikiMD]
* [https://wikimd.org/wiki/Glucagon Glucagon on WikiMD]
* [https://wikimd.org/wiki/Type_2_diabetes Type 2 diabetes on WikiMD]
* [https://wikimd.org/wiki/Obesity Obesity on WikiMD]
* [https://wikimd.org/wiki/Weight_loss Weight loss on WikiMD]
* [https://wikimd.org/wiki/Sleep_apnea Sleep apnea on WikiMD]

==External links==

* [https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf FDA Mounjaro prescribing information]
* [https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf FDA Zepbound prescribing information]
* [https://pi.lilly.com/us/mounjaro-uspi.pdf Mounjaro prescribing information from Eli Lilly]
* [https://pi.lilly.com/us/zepbound-uspi.pdf Zepbound prescribing information from Eli Lilly]
* [https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management FDA - Zepbound approval for chronic weight management]
* [https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea FDA - Zepbound approval for obstructive sleep apnea]
* [https://pubmed.ncbi.nlm.nih.gov/35658024/ SURMOUNT-1 tirzepatide obesity trial - PubMed]
* [https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 SURMOUNT-1 in the New England Journal of Medicine]
* [https://pubmed.ncbi.nlm.nih.gov/34170647/ SURPASS-2 tirzepatide versus semaglutide in type 2 diabetes - PubMed]
* [https://www.nejm.org/doi/full/10.1056/NEJMoa2107519 SURPASS-2 in the New England Journal of Medicine]
* [https://pubmed.ncbi.nlm.nih.gov/40353578/ SURMOUNT-5 tirzepatide compared with semaglutide - PubMed]
* [https://www.nejm.org/doi/10.1056/NEJMoa2416394 SURMOUNT-5 in the New England Journal of Medicine]
* [https://pubmed.ncbi.nlm.nih.gov/37366315/ Retatrutide phase 2 obesity trial - PubMed]
* [https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 Retatrutide phase 2 obesity trial in the New England Journal of Medicine]
* [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00967-0/abstract Retatrutide phase 3 type 2 diabetes study in The Lancet]
* [https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss FDA concerns with unapproved GLP-1 drugs used for weight loss]
* [https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-45198 W8MD Brooklyn appointment request]
* [https://www.patientfusion.com/doctor/prab-tumpati-md-sleep-obesity-48161 W8MD Philadelphia appointment request]
{{GLP-1}}
{{Obesity medicine}}
{{Weight loss}}
</div>
[[Category:W8MD]]
[[Category:Weight loss]]
[[Category:GLP-1]]
[[Category:GLP-1 weight loss]]
[[Category:GIP receptor agonists]]
[[Category:Dual GIP and GLP-1 receptor agonists]]
[[Category:Tirzepatide]]
[[Category:Zepbound]]
[[Category:Mounjaro]]
[[Category:Retatrutide]]
[[Category:Diabetes medications]]
[[Category:Anti-obesity medications]]
[[Category:Medical weight loss]]
[[Category:Obesity medicine]]
[[Category:Chronic weight management]]
[[Category:Prescription weight loss medications]]
[[Category:Weight loss injections]]
[[Category:Type 2 diabetes]]
[[Category:Insulin]]
[[Category:Glucagon]]
[[Category:Appetite]]
[[Category:Satiety]]
[[Category:Food noise]]
[[Category:Gastric emptying]]
[[Category:Sleep apnea]]
[[Category:Brooklyn weight loss]]
[[Category:New York City weight loss]]
[[Category:New Jersey weight loss]]
[[Category:Connecticut weight loss]]
[[Category:Philadelphia weight loss]]
[[Category:Pennsylvania weight loss]]
[[Category:Delaware weight loss]]